Operating Segments (Tables)

12 Months Ended

Dec. 31, 2012

Operating Segments [Abstract]

Summary of segmental information

	For the Year Ended December 31,
	2012			2011
Revenues
Vaccines/BioDefense	$	2,919,677		$	2,010,234
BioTherapeutics 1		224,943			5,652,588
Total	$	3,144,620		$	7,662,822
Loss from Operations
Vaccines/BioDefense	$	(33,636	)	$	(154,395	)
BioTherapeutics		(2,203,721	)		(1,278,156	)
Corporate		(2,453,311	)		(1,527,644	)
Total	$	(4,690,668	)	$	(2,960,195	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	38,589		$	42,640
BioTherapeutics		190,003			181,213
Corporate		2,038			2,174
Total	$	230,630		$	226,027
Interest Income
Corporate	$	6,202		$	7,444
Stock-Based Compensation
Vaccines/BioDefense	$	44,484		$	78,622
BioTherapeutics		84,020			426,666
Corporate		333,666			210,517
Total	$	462,170		$	715,805
	As of December 31,
	2012			2011
Identifiable Assets
Vaccines/BioDefense	$	628,494		$	689,266
BioTherapeutics		566,111			753,767
Corporate		3,510,499			6,780,625
Total	$	4,705,104		$	8,223,658

1 BioTherapeutics revenues for 2011 includes the receipt of a $5 million licensing fee from Sigma-Tau in July 2011.